The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort

Liposomal irinotecan plus 5-fluorouracil/leucovorin (nal-IRI + 5-FU/LV) has shown to provide survival benefits for patients with gemcitabine-refractory metastatic pancreatic ductal adenocarcinoma (PDAC) in NAPOLI-1 trial, in which Asian patients experienced more hematological toxicity and subsequent...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Yung-Yeh, Chiang, Nai-Jung, Tsai, Hui-Jen, Yen, Chia-Jui, Shan, Yan‐Shen, Chen, Li‐Tzong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7198559/
https://www.ncbi.nlm.nih.gov/pubmed/32366911
http://dx.doi.org/10.1038/s41598-020-64421-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7198559/
https://www.ncbi.nlm.nih.gov/pubmed/32366911
http://dx.doi.org/10.1038/s41598-020-64421-6

Ejemplares similares